BDNF and Alzheimer disease: Pharmacogenomic testing can analyze genes such as APOE and BDNF to determine the appropriate selection and dosage of cholinesterase inhibitors and NMDA receptor antagonists in AD (Oddo and LaFerla, 2006; Miller and Seeley, 2013).